Primmune Therapeutics

Primmune Therapeutics is developing oral small molecule Toll-like receptor 7 (TLR7) agonists to stimulate innate immunity in cancer immunotherapy, aiming to enhance patients' response rates to current and future immunotherapy drugs, such as checkpoint inhibitors, to improve overall response rates and treatment durability. The company is also developing TLR7 agonists for the prevention and treatment of viral infections, either as a monotherapy or in combination with direct-acting antiviral agents.